Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer
LiverMWA1
1 other identifier
interventional
19
1 country
1
Brief Summary
Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2008
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
June 1, 2009
CompletedFirst Posted
Study publicly available on registry
June 17, 2009
CompletedNovember 16, 2009
November 1, 2009
8 months
June 1, 2009
November 13, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Variability of ablation diameters
within the first 7 days and 3 months after surgery
Study Arms (2)
MWA
EXPERIMENTALPatients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
RFA
ACTIVE COMPARATORPatients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
Interventions
Liver tumors are destructed/ablated using single-probe microwave energy device
Liver tumors are destructed/ablated using radiofrequency energy device
Eligibility Criteria
You may qualify if:
- Unresectable metastatic liver cancer
- No invasion of major biliary structures
- No invasion of major vascular structures
- ASA score \< 4
- WHO score 0-1
- Pre-operative chemotherapy is allowed
You may not qualify if:
- Resectable liver metastases
- Life expectancy less than 3 months
- Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials
- Coagulopathy with platelet count less than 50000
- Active infectious disease
- Age below 18 years
- Pregnancy of breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Gasthuisberg
Leuven, Vlaams-Brabant, 3000, Belgium
Related Publications (1)
Hompes R, Fieuws S, Aerts R, Thijs M, Penninckx F, Topal B. Results of single-probe microwave ablation of metastatic liver cancer. Eur J Surg Oncol. 2010 Aug;36(8):725-30. doi: 10.1016/j.ejso.2010.05.013. Epub 2010 Jun 3.
PMID: 20605397DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Baki Topal, MD, PhD
Universitaire Ziekenhuizen KU Leuven
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
June 1, 2009
First Posted
June 17, 2009
Study Start
August 1, 2008
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
November 16, 2009
Record last verified: 2009-11